The orthopaedic medical device company Wright Medical has agreed to buy BioMimetic Therapeutics, a company developing regenerative medicine products to promote the healing of musculoskeletal injuries and diseases, for up to US$380 M in a cash and stock deal. Approved by the Boards of Directors of both companies, the deal will expand Wright Medical’s lower extremities franchise and strengthen its biologics platform. BioMimetic is awaiting a regulatory decision from the US FDA on its protein therapeutic product Augment® Bone Graft as a replacement for autologous bone graft in foot and ankle fusions.